Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented, "At the European Society of Cardiology Congress (ESC), beginning August 28, CRISPR Therapeutics will present a late-breaking oral abstract with follow-up data from ANGPTL3- targeting, in vivo gene therapy, CTX310. Following the first detailed clinical update at the American Heart Association (AHA) conference in 2025 and NEJM publication, CRSP has narrowed focus to severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia, indications where gene editing would match the patient's disease burden. With much of the focus of lipid-lowering approaches on PCSK9 and traditional routes of delivery (orals, siRNA, mAbs), CRSP has the potential to deliver a truly differentiated, one-time therapy. We maintain our Market Outperform rating and $80 DCFderived price target ahead of CRSP's late-breaker."

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $57.08 yesterday.